[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"saliva\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:saliva":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,49,85,112,135,175,203,233],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100643279","methylated-biomarkers-of-smoking-as-a-selection-tool-in-participants-for-lung-cancer-screening-100643279",false,"NCT07631624","Methylated Biomarkers of Smoking as a Selection Tool in Participants for Lung Cancer Screening","MET-SELS","Cohort 1: Volunteers\n\nInclusion Criteria:\n\n* Age: Must be \\> 50 years of age\n* Smoking History: Includes individuals with and without a smoking history\n\nCohort 2: ZORALCS-study participants\n\nInclusion Criteria:\n\n* Age: 55-74 years old\n* Smoking History: Includes individuals with a smoking history",true,"ALL","50 Years",{"count":20,"type":21},1000,"ESTIMATED","INTERVENTIONAL",[24],"NA","The MET-SELS study aims to revolutionize how we identify individuals for lung cancer screening by moving beyond the limitations of self-reported smoking history. Currently, eligibility for low-dose CT (LDCT) scans relies on \"pack-years\"-a metric often compromised by recall bias, under-reporting, and an inability to account for the biological nuances of smoke inhalation or environmental exposure. Consequently, current criteria miss nearly half of incidental lung cancers.\n\nTo bridge this gap, the study investigates DNA methylation as a stable, objective \"biological footprint\" of smoking. Unlike short-term biomarkers like nicotine or CO levels, specific epigenetic changes in genes such as AHRR and F2RL3 persist long after cessation and correlate accurately with cumulative tobacco exposure.\n\nLed by Professor Dr. Annemiek Snoeckx and a multidisciplinary team at UZA and the Centre for Medical Genetics, the research will analyze saliva samples from two groups: roughly 900 participants from the ZORALCS screening trial and 150 volunteers. By comparing saliva-derived genomic signatures against both self-reported data and professional interviews, the team aims to validate a panel of methylation markers that can pinpoint high-risk individuals with far greater precision.\n\nThe ultimate vision for MET-SELS is to implement a population-based \"saliva-first\" triage system, similar to the FIT test used for colorectal cancer. In this model, high-risk candidates would provide a saliva sample at home; only those with a confirmed epigenetic risk profile would be invited for a LDCT scan, significantly increasing the yield of early-stage lung cancer detection while streamlining healthcare resources.",[27,28,29,30,31],"Epigenetics","DNA Methylation","Lung Cancer Screening","Risk Stratification With Biomarker","Saliva",[33,29,34,35,31],"DNA-methylation","Risk stratification","Smoking","RECRUITING","2026-06-03",{"date":39,"type":40},"2026-06-08","ACTUAL",{"date":42,"type":40},"2025-10-04",{"date":44,"type":21},"2028-01-01",{"name":46,"class":47},"University Hospital, Antwerp","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":70,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":48},"100640010","mobile-dual-task-brain-and-balance-intervention-for-concussion-recovery-100640010","NCT07599475","Mobile Dual-Task Brain and Balance Intervention for Concussion Recovery","Boosting Brain and Balance: A Mobile Dual-Task Intervention for Athletes With Concussion and Mild Traumatic Brain Injury (mTBI)","Inclusion Criteria:\n\n* Adults aged 18 to 40 years\n* Self-reported history of sports-related concussion (SRC) or mild traumatic brain injury (mTBI) within the past 3 to 12 months\n* Meets criteria for mTBI based on a standardized screening method (e.g., Ohio State University TBI Identification Method)\n* Able to safely participate in light physical activity (e.g., walking) and simple cognitive tasks based on self-report and observational screening by the research team\n* Able to read and understand English (if applicable for study materials)\n* Able to provide informed consent\n* Has access to and is able to use a smartphone or mobile device to complete daily app-based activities\n\nExclusion Criteria:\n\n* Age younger than 18 years or older than 40 years\n* History of moderate or severe traumatic brain injury\n* Concussion or mTBI occurring less than 3 months or more than 12 months prior to enrollment\n* Self-reported active medical disease or history of neurological or psychiatric conditions unrelated to concussion\n* Self-reported other medical conditions that would limit safe participation in light physical activity (e.g., walking or balance tasks)\n* Currently on prescribed medications that may significantly affect cognitive function, balance, neurological function, or safe participation in light physical activity\n* Inability to use a smartphone or mobile device required for study participation\n* Inability to read or understand English (as study materials and the mobile application are currently available only in English)","18 Years","40 Years",{"count":59,"type":21},20,[24],"This research study examines recovery after a sports-related concussion or mild head injury. Many athletes experience lingering problems with thinking, balance, and mood months after a concussion.\n\nWe are testing a new home-based program called BraW-Day™ (Brain \\& Walk Exercise Every Day). This 14-day program uses a mobile app on your smartphone and combines simple brain exercises (like counting backwards) with walking exercises. The idea is that doing these tasks together may help your brain and body recover more effectively.\n\nWhat You'll Do:\n\n* Two in-person visits at UNLV (baseline and after 14 days) for assessments\n* Daily 15-minute exercises at home using the BraW-Day app\n* Provide a small saliva sample for biomarker testing\n* Complete brief questionnaires about your symptoms and health\n\nPotential Benefits:\n\nYou may experience improvements in thinking, balance, or mood. Even if you don't benefit directly, your participation will help researchers understand how to better support athletes recovering from concussion.\n\nWho Can Join:\n\n* Ages 18-40\n* Had a sports-related concussion or mild head injury within the past 3-12 months\n* Have a smartphone and can safely do light walking and simple tasks\n\nThis study is registered at ClinicalTrials.gov and approved by the UNLV Institutional Review Board to protect your safety and rights.",[63,64,65,66,67,31,68,69],"Mild Traumatic Brain Injury (mTBI)","Sports-related Concussion","Heart Rate Variability (HRV)","Walking","Oculomotor","Exosomal microRNA","Cognitive Function",[71,72,73,74],"dual-task","mild traumatic brain injury (mTBI)","sports-related concussion","BraW-Day","NOT_YET_RECRUITING","2026-05-14",{"date":78,"type":40},"2026-05-20",{"date":80,"type":21},"2026-05-15",{"date":82,"type":21},"2027-04-30",{"name":84,"class":47},"Hyunhwa Lee",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":100,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":48},"100500045","epigenetic-biomarkers-in-the-saliva-for-the-diagnosis-of-squamous-cells-carcinoma-of-the-oral-cavity-100500045","NCT05791149","Epigenetic Biomarkers in the Saliva for the Diagnosis of Squamous Cells Carcinoma of the Oral Cavity","EPSACO","Inclusion Criteria:\n\n* Patient group:\n* Patients from the maxillofacial surgery department treated for a histologically confirmed squamous cell carcinoma of the oral cavity\n* Patients whose first-line treatment decision at the multidisciplinary meeting in the service of Maxillofacial Surgery is surgery\n* Patients who have not yet been treated surgically or by neoadjuvant treatment\n* Patients over 18 years old\n* Patients who have provided free and informed consent in writing\n* Patients benefiting from a social security scheme\n\nControl group:\n\n* Patients in the maxillofacial surgery department not covered for head and neck cancer\n* Patients over 18 years old\n* Patients who have provided free and informed consent in writing\n* Patients benefiting from a social security scheme\n* Control group homogeneous with the patient group according to age, sex, tobacco and alcohol consumption\n\nExclusion Criteria:\n\n* Patients with other types of cancer\n* Patients under the age of 18\n* Pregnant or breastfeeding women\n* Patients under guardianship, curators, legal protection or deprived of liberty",{"count":93,"type":21},60,[24],"Head and neck squamous cell carcinoma (HNSCC) are malignant tumors originating from the epithelial mucosa of the upper aerodigestive tract. The oral cavity is the most frequent location of HNSCC (oral squamous cell carcinoma: OSCC). Tobacco use and alcohol consumption are the greatest risk factors. The Hauts de France region has one of the highest incidence rates of OSCC. The overall survival of patients with OSCC remains low, with a 5-year overall survival rate of around 60%. In addition to the oncological prognosis, OSCCs and their treatment have a significant impact on the quality of life of patients. An early diagnosis of OSCC is recommended, but it remains difficult. It can be for example challenging to diagnose OSCC in a context of oral premalignant lesions. Identifying objective biomarkers of malignancy would be an advantage and would allow better progress in the field of precision medicine and surgery for these tumors.\n\nThe investigators propose to establish the diagnostic use of an optimized DNA methylation profile detected in the saliva of OSCC patients by comparing these epigenetic marks before and after tumor resection.\n\nThe investigators will construct a consolidated signature of 4 genes whose DNA is subject to methylation and gene expression is restricted to cancer cells, by crossing TCGA analysis with single-cell analysis (single-cell RNA sequencing).\n\nThe investigators propose to analyse DNA methylation of the corresponding genes in the saliva of n=30 OSCC patients recruited for primary surgical resection in the Department of Maxillofacial Surgery vs controls. In addition, the investigators will examine the methylation profiles before \u002F after complete excisional surgery of OSCC. This pilot study will aim to validate the analysis of DNA methylation markers in saliva of OSCC, with the aim of improving the diagnostic precision of OSCC and, secondly, to compare these markers before and after treatment by primary surgery.",[97,98,99,31,28,27],"Oral Squamous Cell Carcinoma","Maxillo-facial Surgery","Biomarkers",[97,101,99,31,28,102],"Maxillo-facial surgery","epigenetics","2026-05-12",{"date":105,"type":40},"2026-05-13",{"date":107,"type":40},"2022-03-03",{"date":109,"type":21},"2027-10",{"name":111,"class":47},"Centre Hospitalier Universitaire, Amiens",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":16,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":118,"targetDuration":120,"studyType":121,"phases":4,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":48},"100615505","discovery-and-validation-of-periodontitis-biomarkers-100615505","NCT07293481","Discovery and Validation of Periodontitis Biomarkers","Inclusion Criteria:\n\n1. Adults between 18 and 40 years of age;\n2. Diagnosed with varying degrees of periodontal disease, including gingivitis and stage I periodontitis;\n3. Voluntarily agree to participate in the study, have signed the informed consent form, and are able to comply with the study protocol.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women;\n2. Individuals who have received antibiotic treatment within the past 3 months;\n3. Individuals who have received periodontal treatment (including supragingival scaling) within the past 6 months;\n4. Individuals with mucosal or salivary gland diseases (e.g., Sjögren's syndrome);\n5. Individuals with severe systemic diseases, immune dysfunction, or health conditions that contraindicate surgery;\n6. Individuals who are unwilling to cooperate with the study.",{"count":119,"type":21},228,"2 Years","OBSERVATIONAL","Periodontitis is a major public health issue in China: it is responsible for loss of masticatory function in 60 million older adults, and 400-500 million adults are on the same disease trajectory. In addition, gingivitis and early-stage periodontitis are highly prevalent in all age groups. The Lancet 2021 burden of disease study provides worrying projections for China's oral health, with a 47.8% increase in advanced-stage periodontitis and a 217% increase in edentulism by the year 2050. The numbers are not manageable by the Chinese health system unless a series of coordinated actions are implemented: i) health education promoting oral hygiene in school and the workplace; ii) effective AI-based self-detection strategies and accurate identification of high-risk subjects; iii) efficient treatment modalities; and iv) reorganization of the health system.\n\nWe have developed, patented, and validated a self-detection AI-based screening test for the general population through an app. It is based on a few validated questions and the performance of a lateral flow immunoassay to detect activated matrix metalloproteinase 8 (aMMP8). The algorithm enables accurate self-detection of severe periodontitis. The system, however, cannot identify subjects without clinically evident periodontitis (subjects who present with superficial inflammation consistent with gingivitis and incipient periodontitis) who will develop the disease, which, therefore, should be the target of early interventions. This limitation is due to insufficient knowledge of the process that turns superficial inflammation (gingivitis) into periodontitis. This limitation is apparent in the recently published NIH-sponsored American diagnostic trial results to detect periodontitis onset biomarkers (and progression). In their study, Teles et al. (2024) show that almost 24% of gingivitis subjects progress to periodontitis over a 12-month period but failed to identify salivary or serum biomarkers. Similarly, our recently completed study (Li et al. in preparation) did not identify highly accurate biomarkers for disease onset and progression. Importantly, the American and our study have tested putative biomarkers identified based on the current crude knowledge of the disease process. Gaps in fundamental knowledge are now apparent and limit our ability to detect periodontitis early. In addition, the current crude differential diagnosis based on clinical examination with a periodontal probe with millimeter markings cannot accurately differentiate gingivitis from early-stage periodontitis, complicating the ground truth definition (gold standard).\n\nIn the current study, we propose implementing a multi-omics approach to test the ability to discriminate a mixed population of clinically undifferentiable gingivitis and stage I periodontitis into two or more clusters. In this biomarker discovery phase, we plan to use multiple state-of-the-art methods: i) laser scanning microdissection proteomics of tissue biopsies, ii) conventional salivary proteomics, iii) tissue biopsy transcriptomics, and iv) shotgun microbiome analysis. The methods will be applied in an agnostic approach to test the following hypotheses:\n\n1. It is possible to identify two or more clusters of subjects from a mixed population of gingivitis and stage I periodontitis subjects.\n2. The clusters differ based on host-derived biomarkers and\u002For microbiome factors and the risk of progression to periodontitis.\n3. The biomarker pathways and microbial virulence factors among subjects identified according to the different approaches used to explore disease biology are generally consistent.\n4. It is possible to identify a limited set of biomarkers that can be used to predict periodontitis onset and thus target early interventions for this high-risk population.",[124,125,31],"Periodontitis","Biomarker in Early Diagnosis","2026-04-17",{"date":128,"type":40},"2026-04-20",{"date":130,"type":40},"2025-07-21",{"date":132,"type":21},"2027-10-31",{"name":134,"class":47},"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":156,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":48},"100488116","effect-of-a-novel-topical-composition-on-the-incidence-of-severe-oral-mucositis-in-head--neck-cancer-radiated-patients-and-quality-of-life-assessed-by-proms-100488116","NCT05635929","Effect of a Novel Topical Composition on the Incidence of Severe Oral Mucositis in Head & Neck Cancer Radiated Patients and Quality of Life Assessed by PROMs.","Effect of a Novel Topical Composition on the Incidence of Severe Oral Mucositis in Head & Neck Cancer Radiated Patients and Quality of Life Assessed by PROMs. A Two Phases Study, Part of STOP OM PROJECT. Phase 2, Single Arm, Interventional, Longitudinal, Clinical Trial.","STOPOMP","Inclusion Criteria:\n\nAcute Phase\n\n* Patients diagnosed with Head \\& Neck cancer who will undergo radiotherapy (with or without concomitant chemotherapy)\n* Patients who are able to read, understand, and complete the questionnaire.\n* Patients over 18 years of age.\n\nChronic Phase\n\n* Patients who have completed radiotherapy treatment at least 6 months before study enrollement.\n* Patients who are able to read, understand, and complete the questionnaire.\n* Patients over 18 years of age.\n\nExclusion Criteria:\n\nAcute Phase\n\n* Patients who are unable to properly use the products.\n* Patients who do not consent to participate in the study.\n* Patients who were being treated for another type of cancer.\n\nChronic Phase\n\n* Patients using medications such as pilocarpine, cevimeline, etc., to treat xerostomia.\n* Patients who do not consent to participate in the study.",{"count":144,"type":21},63,[24],"The use of a novel topical mucosa composition (XCM-OM118) comprising 2-(trimethylazaniumyl) acetate; (2R,3R,4S)-pentane-1,2,3,4,5-pentol; Hexadecanoic acid; (9Z, 12Z)-octadeca-9,12-dienoic acid; octadecanoic acid; (Z)-hexadec-9-enoic acid; (Z)-octadec-9-enoic acid) delivered as a gel and a mouthwash is to be studied in regard to its effect on the incidence of severe oral mucositis in Head \\& Neck cancer radiated patients. Patient reported outcome measures seem to be an effective tool to obtain a greater knowledge of the physical and emotional state of patients, being used in this study to assess quality of life of Head \\& Neck cancer radiated patients.",[148,149,150,151,152,31,153,154,155],"Oral Mucositis","Quality of Life","Mucositis","Pain","Speech","Radiation Toxicity","Chemotherapeutic Toxicity","Head and Neck Cancer",[148,157,158,151,159,160,161,162,163,155,164],"Cancer Therapy Toxic Effect","Cancer Support","Ulcers","Treatment Interruptions","Oral Mucosa","Radiotherapy","Chemotherapy","Severe Oral Mucositis","2026-04-10",{"date":167,"type":40},"2026-04-15",{"date":169,"type":40},"2022-10-11",{"date":171,"type":21},"2027-03",{"name":173,"class":174},"Mucosa Innovations, S.L.","INDUSTRY",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":48},"100623533","salivary-flow-ph-and-buffering-capacity-in-fixed-and-clear-aligner-orthodontic-treatment-100623533","NCT07397871","Salivary Flow, pH, and Buffering Capacity in Fixed and Clear Aligner Orthodontic Treatment","Changes in Salivary Parameters in Patients Undergoing Clear Aligner Orthodontic Treatment: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Class I, II and III skeletal malocclusion.\n* Age ≥18 undergoing fixed or Clear aligner orthodontic treatment.\n\nExclusion Criteria:\n\n* Current medications including antibiotic use within the past 3 months that affect salivary flow and composition.\n* Active smoking including vaping and E-cigarette use.\n* Diagnosis of systemic diseases\u002Fconditions such as Sjogren's syndrome, diabetes, chronic kidney diseases, neurological conditions.\n* Active dental caries or signs of gingivitis and\u002For periodontitis\n* Less than three months of orthodontic treatment since it is characterized by acute, temporary changes and patient adaptation to the new appliances.\n* Requiring single arch treatment to standardize the research and eliminate a potential confounding variable\n* Crown restoration is excluded due to their material properties which may affect salivary composition.\n* Pregnancy due to the physiological variation in salivary flow and composition due to hormonal changes.\n* Presence of mouth breathing may lead to inconsistent salivary flow rate, Changes in Salivary Composition and pH\n* Poor oral hygiene with high levels of dental plaque, calculus, and gingival inflammation can independently alter salivary flow rate, pH, and buffer capacity there by acting as confounding variable.",{"count":183,"type":21},40,[24],"Study Design: A randomized controlled trial with two parallel arms and an allocation ratio of 1:1.\n\nSetting: The study will be conducted in the orthodontic department of Riyadh Elm University hospitals in Riyadh City, Saudi Arabia.\n\nParticipants: Patients undergoing fixed or clear aligner orthodontic treatment referred to REU dental hospital will be randomly allocated to either the clear aligner group or the fixed orthodontic appliance group.\n\nIntervention: Prior to orthodontic treatment, all patients will receive phase I periodontal therapy and oral hygiene instructions. Fixed orthodontic appliances will be bonded using metallic brackets with a 0.022-inch slot and 0.014-inch NiTi archwires. Clear aligner patients will receive Invisalign® treatment.\n\nOutcomes and Saliva Collection: Salivary samples will be collected using the spitting method at baseline (T0) and follow-up time points according to the study protocol. Salivary flow rate, pH, and buffering capacity will be assessed as described in the proposal.\n\nRandomization and Blinding: Randomization will be performed using a random number generator with allocation concealment via opaque envelopes. The investigators involved in outcome assessment and data analysis will be blinded.\n\nEthical Considerations: The study will be submitted to the Institutional Review Board at Riyadh Elm University and conducted in accordance with IRB policies.",[187,31],"Orthodontic Treatment",[189,190,191,192,193],"Salivary flow","Salivary pH","Buffering capacity","Fixed orthodontic appliance","Clear aligner therapy","2026-02-02",{"date":196,"type":40},"2026-02-09",{"date":198,"type":21},"2026-03-15",{"date":200,"type":21},"2027-05-29",{"name":202,"class":47},"Riyadh Elm University",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":16,"sex":17,"minAge":56,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":214,"conditions":215,"keywords":219,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":4},"100612473","ai-assisted-saliva-diagnostics-using-an-electrochemical-sensor-platform-for-periodontitis-detection-salience-100612473","NCT07254039","AI-Assisted Saliva Diagnostics Using an Electrochemical Sensor Platform for Periodontitis Detection (SALIENCE)","Development and Validation of an AI-Assisted Electrochemical Sensor Platform for Saliva-Based Diagnostics in Periodontitis","SALIENCE","Inclusion Criteria:\n\nAdults ≥18 years.\n\nAble and willing to provide written informed consent.\n\nAbility to provide an unstimulated whole saliva sample per protocol (no food, drink, gum, toothbrushing, or smoking within 60 minutes prior to sampling).\n\nPeriodontitis group: Clinical diagnosis of periodontitis according to 2018 AAP\u002FEFP criteria (e.g., interdental CAL ≥3 mm at ≥2 non-adjacent teeth with radiographic bone loss; probing pocket depth ≥4 mm in ≥2 teeth).\n\nHealthy control group: No clinical signs of periodontal disease (no probing depths \\>3 mm, bleeding on probing \\\u003C10%, and no radiographic bone loss).\n\nExclusion Criteria:\n\nSystemic antibiotics or systemic anti-inflammatory\u002Fimmunosuppressive therapy within the past 3 months.\n\nPeriodontal therapy (scaling\u002Froot planing or surgery) within the past 6 months.\n\nCurrent acute oral infection or abscess.\n\nSystemic conditions known to markedly alter saliva composition\u002Fflow (e.g., Sjögren's syndrome, prior head-and-neck radiation, ongoing chemotherapy, uncontrolled diabetes).\n\nUse of strongly xerogenic medications not on a stable dose ≥4 weeks, or clinically significant hyposalivation preventing sampling.\n\nInability to comply with sampling procedures (e.g., cannot abstain from food\u002Fdrink\u002Ftobacco for 60 minutes prior to sampling).\n\nPregnancy or lactation.","80 Years",{"count":213,"type":21},200,"This observational study aims to develop and validate a novel, AI-assisted electrochemical sensor platform for saliva-based diagnostics in periodontitis. Periodontitis is a chronic inflammatory disease affecting the gums and supporting tissues of the teeth. Despite its high global prevalence, early diagnosis remains challenging because the disease often progresses silently until irreversible damage has occurred.\n\nSaliva offers a promising, non-invasive diagnostic medium that reflects both oral and systemic health. However, its biological complexity and variability have limited its clinical use. This project addresses these challenges by combining advanced electrochemical sensing with artificial intelligence (AI) and synthetic data generation to improve diagnostic precision and reliability.\n\nThe study involves the collection of saliva samples from adult participants with diagnosed periodontitis and from healthy controls. The samples will be analyzed using a modular sensor platform equipped with multiple electrodes that detect electrochemical signals from a wide range of salivary biomarkers. The sensor data will then be processed using machine learning models trained on both real and synthetic data to classify disease states.\n\nThe main goals are to:\n\nEvaluate the performance of the electrochemical sensor array for saliva analysis.\n\nDevelop and validate AI-based algorithms for detecting and differentiating between healthy and diseased samples.\n\nGenerate feasibility data supporting future clinical implementation of saliva-based diagnostics for periodontitis.\n\nThis interdisciplinary project combines expertise in clinical dentistry, biomedical engineering, and computer science. It is conducted in collaboration between Linköping University and Malmö University, with patient sampling carried out at an affiliated dental clinic.\n\nThe study is expected to result in a working proof-of-concept device that enables real-time, non-invasive detection of periodontitis at the point of care. By enabling earlier diagnosis and more personalized treatment, this technology may transform periodontal care and serve as a foundation for future saliva-based diagnostics targeting other oral and systemic diseases.",[216,217,218,31],"Periodontal Diseases","Biomarkers (D23.050.301)","Diagnostic",[220,221,222,99,223],"Saliva Diagnostics","Electrochemical Sensor","AI-Assisted Diagnostics","Periodontal diseases","2025-11-19",{"date":226,"type":40},"2025-11-28",{"date":228,"type":21},"2025-12-01",{"date":230,"type":21},"2028-06-30",{"name":232,"class":47},"Ostergotland County Council, Sweden",{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":17,"minAge":240,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":22,"phases":243,"briefSummary":244,"conditions":245,"keywords":248,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":48},"100537323","influence-of-timing-of-implant-placement-on-early-healing-molecular-events-100537323","NCT06276335","Influence of Timing of Implant Placement on Early Healing Molecular Events","Influence of Timing of Implant Placement on Early Healing Molecular Events: A Two-centre, Parallel Group, Pilot Study","Inclusion Criteria:\n\n* Age ≥25 years old\n* Good\u002Fcontrolled medical and psychological health\n* Good oral hygiene (FMPS≤20%)\n* Presence of a tooth in the aesthetic region (from incisor to second premolar) in need of extraction and further oral rehabilitation with a single dental implant.\n* For the IP group, the extraction socket should fulfil the following parameters, as described by the 5th ITI consensus \\[46\\]: intact socket wall; facial bone wall ≥1mm in thickness; no acute infection at the site; availability of bone apical and palatal to the socket to provide primary stability.\n* At least one neighbouring natural tooth.\n* A functional occlusion with a minimum of four occlusal units (i.e., pairs of occluding posterior teeth).\n* Willingness to read and sign a copy of the Informed Consent Form (ICF) after reading the Patient Information Sheet (PIS), and after the nature of the study has been fully explained and potential questions fully answered.\n\nExclusion Criteria:\n\n* Any known systemic disease severely affecting bone metabolism (e.g., Cushing's syndrome, Crohn's disease, rheumatoid arthritis, osteoporosis or diabetes type I and uncontrolled diabetes type II).\n* Self-reported HIV or viral hepatitis.\n* Self-reported alcoholism or chronic drug abuse.\n* Smokers (including current smokers or former smokers who had quit for \\\u003C 3 months); patients reporting use of vape\u002Fe-cigarettes will also be excluded.\n* Self-reported pregnancy or lactation (this criterion is due to oral tissue changes related to pregnancy and nursing, which can affect interpretation of study results).\n* Chronic treatment (i.e., 2 weeks or more) with any medication known to affect oral status or bone metabolism (e.g., bisphosphonates, hormone replacement therapy, immunosuppressants) within 1 month before baseline visit.\n* Chronic treatment with anticoagulants (including Aspirin), corticosteroids, immunosuppressants or other medications that may influence blood coagulation\u002Fcount.\n* Antibiotic or anti-inflammatory therapy during the month preceding the baseline exam.\n* Untreated caries lesions and untreated\u002Funcontrolled periodontal disease; If patients require periodontal treatment (non-surgical and\u002For surgical), this will be arranged outside the study protocol and completed prior to enrolment;\n* Inadequate keratinized tissue width (\\\u003C2 mm) in the mid-buccal aspect of the area to be treated in the study.\n* Physical handicaps that would interfere with the ability to perform adequate oral hygiene in the area of implant placement.\n* Patients requiring maxillary sinus lift surgery before implant placement.\n* Self-reported bruxism.\n* Patients not willing to receive animal-derived biomaterials for GBR.\n* Patients suffering from a known psychological disorder or with limited mental capacity or language skills such that study information could not be understood, informed consent could not be obtained, or simple instructions could not be followed.\n* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgement of the investigator, would make the subject inappropriate for entry into this trial.","25 Years",{"count":242,"type":21},24,[24],"Dental implants have been on the market for several years and they are routinely used to replace single\u002Fmultiple missing teeth with a high success rate. However, there is still a limited number of studies comparing the influence of timing of implant placement on wound healing. In addition, there is no data available on the signaling pathways and the expression of healing biomarkers involved in the early stages of osseointegration after immediate implant placement (IP) or delayed implant placement (DP).\n\nThe primary objective of this study is to describe changes in the expression of inflammatory, angiogenesis and osseous biomarkers of saliva at 1, 3, 7, 15 and 30 days and of PICF at 3, 7, 15 and 30 days after immediate implant placement (IP) compared with delayed placement (DP).",[246,247,99,31],"Dental Implant","Healing Wound",[249],"Implant placement protocol","2025-11-17",{"date":224,"type":40},{"date":253,"type":40},"2024-09-26",{"date":255,"type":21},"2026-12-31",{"name":257,"class":47},"Queen Mary University of London"]